Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, updates the public on the trial results (which he was a lead author of) and how the use of precision medicine guidelines played a role.
Master Protocols: Implementing Effective Treatment Adaptations in the Randomization
August 23rd 2023It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.